A team from Massachusetts General Hospital and Harvard Medical School (United States) has developed a method based on artificial intelligence to examine drugs already available as possible treatments for Alzheimer’s disease.
The method could represent a quick and inexpensive way to convert existing therapies into new treatments for this progressive and debilitating neurodegenerative disease. Most importantly, it could also help reveal new unexplored therapeutic targets by pinpointing drug mechanisms of action.
” Re-adaptation of drugs already approved for Alzheimer’s disease is an attractive idea that can help accelerate the arrival of an effective treatment, but unfortunately, even for previously approved drugs, clinical trials require substantial resources. that it is impossible to evaluate all drugs in patients with Alzheimer’s disease. Therefore, we built a framework to prioritize drugs, helping clinical studies to focus on the most promising “, explains one of the study leaders, Artem Sokolov.